159 related articles for article (PubMed ID: 32978946)
1. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease.
Rinawi F; Ricciuto A; Church PC; Frost K; Crowley E; Walters TD; Griffiths AM
Inflamm Bowel Dis; 2021 Jun; 27(7):1079-1087. PubMed ID: 32978946
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease: Associations With Adalimumab Exposure.
Rinawi F; Popalis C; Tersigni C; Frost K; Muise A; Church PC; Walters TD; Ricciuto A; Griffiths AM
J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):389-395. PubMed ID: 35226647
[TBL] [Abstract][Full Text] [Related]
3. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
5. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
Zittan E; Steinhart AH; Goldstein P; Milgrom R; Gralnek IM; Silverberg MS
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00401. PubMed ID: 34613952
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab Therapy in Pediatric Crohn Disease: A 2-Year Follow-Up Comparing "Top-Down" and "Step-Up" Strategies.
Payen E; Neuraz A; Zenzeri L; Talbotec C; Abi Nader E; Chatenoud L; Chhun S; Goulet O; Ruemmele FM; Pigneur B
J Pediatr Gastroenterol Nutr; 2023 Feb; 76(2):166-173. PubMed ID: 36305799
[TBL] [Abstract][Full Text] [Related]
8. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
Wright EK; Chaparro M; Gionchetti P; Hamilton AL; Schulberg J; Gisbert JP; Chiara Valerii M; Rizzello F; De Cruz P; Panetta JC; Everts-van der Wind A; Kamm MA; Dervieux T
J Crohns Colitis; 2024 Feb; 18(2):212-222. PubMed ID: 37594369
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
11. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients.
Choi SY; Choi YO; Choe YH; Kang B
J Korean Med Sci; 2020 Apr; 35(16):e114. PubMed ID: 32329259
[TBL] [Abstract][Full Text] [Related]
12. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.
Matar M; Shamir R; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Ben-Horin S; Assa A
Inflamm Bowel Dis; 2020 Oct; 26(11):1627-1635. PubMed ID: 31793630
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
[TBL] [Abstract][Full Text] [Related]
15. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease.
Nakase H; Matsumoto T; Watanabe K; Hisamatsu T
J Gastroenterol; 2020 Sep; 55(9):824-832. PubMed ID: 32661927
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP;
Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204
[TBL] [Abstract][Full Text] [Related]
17. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
19. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
20. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.
Walters TD; Faubion WA; Griffiths AM; Baldassano RN; Escher J; Ruemmele FM; Hyams JS; Lazar A; Eichner S; Huang B; Li Y; Thakkar RB
Inflamm Bowel Dis; 2017 Jun; 23(6):967-975. PubMed ID: 28301428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
